Drug Development

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

Paris-based Ennov lands a major transatlantic investment to accelerate its AI platform, aiming to reshape global drug development and regulatory processes.

A novel drug is in clinical trials for depression, moving beyond neurotransmitters to target the brain's fundamental energy production and repair mechanisms.

A new clinical trial is testing a device that uses electricity to deliver chemo directly into tumors, a strategy that could revolutionize treatment.

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

A first-in-class drug for anxiety has entered patient trials, offering a novel approach that could reshape mental healthcare for millions.

Led by OrbiMed, the financing will propel Accro's promising oral RIPK2 inhibitor for Ulcerative Colitis into a pivotal Phase IIb clinical trial.

A new partnership aims to solve one of biotech's biggest challenges, expanding powerful gene therapies beyond the liver to treat a wider range of diseases.

Ozari Health launches a nationwide service for affordable compounded semaglutide, navigating a complex and increasingly regulated market for GLP-1 drugs.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

New projects leverage AI, gene therapy advances, and diverse workforce initiatives to bolster America's manufacturing and secure its talent pipeline.

Renowned cancer researcher Dr. Dario Altieri leaves a top CEO post to return to the lab at Jefferson, signaling a major shift in Philadelphia's science scene.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

Lexitas acquires Erie Retina Research, CASExERIE, and Element Erie to create an integrated platform, aiming to dominate ophthalmic clinical trials.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.